MedTrace Logo

Study of BW-50218 in Healthy Participants

NCT07401472 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-13

No results posted yet for this study

Summary

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Conditions

  • Healthy Participants Study

Interventions

DRUG

BW-50218 Injection

Solution for injection

DRUG

Saline (0.9% NaCl)

Solution for injection

Sponsors & Collaborators

  • Shanghai Argo Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuqiong Li, MD · Shanghai Argo Biopharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-12
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07401472 on ClinicalTrials.gov